Blueprint Genetics secured more capital investment in the company.
Blueprint Genetics, a Helsinki, Finland-based gene diagnostics company, completed a new capital investment round.
Blueprint Genetics was founded in 2012 as a spinoff from Stanford University. The company, led by CEO Tommi Lehtonen, provides world-class genetic diagnostics and clinical interpretation for hereditary diseases. It covers more than 2,500 genes with our NGS platform, provide more than 220 targeted panels and world-class Whole Exome Sequencing.
In 2018 the company had EUR 15M ($16.5M) in sales. Prior to this round, Blueprint Genetics raised about $26M from outside investors.